Advanced melanoma is a highly aggressive tumor with a low response rate to the majority of pharmacological agents.
or in combination with dacarbazine. The efficacy of Ipilimumab was confirmed both in treated and untreated metastatic melanoma patients [ , , ]. Furthermore, re-treatment with Ipilimumab can re-establish disease control in a percentage of patients who progress after achieving an objective response or stable disease after the first treatment course [ , , -] .
As a consequence of this peculiar mechanism of action, Ipilimumab may determine the development of autoimmune conditions and exacerbate a series of immune-related adverse events, which will be described in the next section of this review.
Vemurafenib is a low molecular weight molecule . Da , orally available, which belongs to the new generation inhibitors of B-Raf as well as of other members of the RAF kinase family including the products of ARAF, BRAF and CRAF genes . The BRAF protein is a part of the RAS/RAF/MEK/ERK signaling pathway, which is a key regulator of melanoma cell growth. In cells expressing the pro-oncogenic BRAF-V E, BRAF-V D and BRAF-V R genes, Vemurafenib inhibits both phosphorylated ERK pERK and pMEK in a dosedependent manner, resulting in a reduction of tumour growth and even in tumour regression in in vitro studies and xenograft transplant models. Several clinical trials have confirmed and extended these preclinical observations and, to date, RAF inhibitors represent the emerging standard of care for metastatic melanoma harboring the BRAF-V E mutation, with clinical responsiveness in more than % of these patients [ , ] . In particular, results from a phase III clinical trial of patiente expressing the BRAF-V E mutated isoform affected by unresectable or metastatic melanoma showed a median overall survival significantly higher for Vemurafenib-treated patients,in comparison to those treated with dacarbazine . vs . months, respectively .
Even if the toxicity of this treatment is normally considered to be acceptable, Vemurafenib triggers the onset of a wide spectrum of systemic and cutaneous toxicities which can impact patient's quality of life in a significant way [ -] . The adverse effects, which will be detailed later, are dose-dependent and related to the alteration of the cell-signaling pathway in response to B-Raf inhibition in cells expressing the wild-type BRAF gene [ ].
.
Ipilimumab toxicities
The onset of immune-related adverse events irAEs during the treatment with Ipilimumab is consequent to action on the immune system. Actually, CTLA-blockage removes CTLAmediated downregulation of the immune response, leading thus to a large spectrum of autoimmune-inflammatory side effects with a dose-dependent mechanism [ ]. These irAEs are described both at the currently approved mg/kg dose and at the investigational mg/kg dose and may affect a number of organs and systems, including the eye, the skin, the gut and the endocrine system.
In a retrospective analysis of phase I-III Ipilimumab trials on patients with advanced melanomas, the occurrence of irAEs of any grade was a quite common phenomenon, regarding about % of the patients [ ]. Nevertheless, Ipilimumab can be considered a safe drug irAEsrelated deaths occurred only in about % of treated patients [ ]. In these trials, the most common immune side effects were represented by enterocolitis, dermatitis, hepatitis, hypo-physitis, and uveitis, usually with an early onset. More recent data obtained on an Italian multicentric expanded-access cohort reported an occurrence of irAEs of any grade in % of treated patients, with a median time of onset of weeks. Most irAEs were low grade, whereas grade / irAEs were described in % of the cases and were most commonly represented by diarrhea, liver toxicity and fatigue/asthenia [ ]. 
IrAE
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In phase I-III studies, irAE resolution time varied from . to . weeks, whereas in patients included in the expanded-access projects ranged from . to . weeks median . weeks . When grade / irAE were separately analyzed the median resolution time was . weeks range, . -. weeks [ , ] . Despite some early findings, no relationship seems to exist between clinical benefit and irAEs onset in treated patients.
Grade / events take advantage from symptomatic treatments and the use of topical steroids, whereas early administration of high-dose systemic corticosteroids is mandatory for the right management of grade / irAEs. Specific guidelines to manage irAEs are available [ , ] . In literature are available guidelines to manage Ipilimumab side effects see 
. Cutaneous side effects from Ipilimumab
Systemic side effects from Ipilimumab are usually dose-related. However, the incidence and severity of pruritus or skin reactions appear independent of Ipilimumab dosage, as demonstrated by a meta-analysis of the studies in which Ipilimumab was administered as monotherapy at different doses mg/kg vs mg/kg , Commonly used targeted anticancer agents e.g. erlotinib, cetuximab, panitumumab, vandetanib, pertuzumab usually induce a characteristic papulopustular acneiform rash in % to % of treated patients. Conversely, Ipilimumab-induced maculo-papular rash are more similar to those commonly seen with traditional drugs ie, antibiotics, non steroidal antiinflammatory drugs or shows clinical characteristics mimicking atopic dermatitis [ ].
From a recent meta-analysis performed on studies from -, which included several trials testing Ipilimumab as monotherapy or in combination at various doses in randomized multi-arm and single-arm studies [ ], emerged that the overall incidence of all-grade rash was . %. The overall incidence of high-grade rash was . %, with a relative risk ranging from . % to . %. Interestingly, among patients receiving mg/kg and receiving mg/kg, there was no significant difference in terms of incidence of all-grade or high-grade rash between doses [ ]. Skin irAEs have a shorter time of onset than those affecting other sites and usually develop -weeks after Ipilimumab initiation.
In our series of patients treated with Ipilimumab, the incidence of cutaneous side effects was % any grade . Ipilimumab-related skin lesion were erythematous, edematous or maculo-papular, often located on the trunk and extremities Figure vasculitic and purpuric lesions were also observed. Pruritus was present in almost half of the patients who showed skin reactions [unpublished data]. Some literature reports suggest that rash can coincide with the regression of subcutaneous disease and may be especially pronounced around nevi, suggesting the presence of an underlying inflammatory response against melanocytes [ -] . The onset of vitiligo-like lesions during Ipilimumab treatment is also a finding related to an immune activation status of the host, and was a relatively common event in our experience [personal unpublished data] , as well as in other case reports [ ].
From a histological point of view, skin biopsies of Ipilimumab-related skin lesions showed a perivascular inflammatory infiltrate in the superficial dermis that extend to the epidermis with CD + and CD + T cells that are CD +. Eosinophils may also be present [ -] .
. Vemurafenib toxicities
Even if Vemurafenib is generally a safe and well-tolerated drug, a wide spectrum of toxic effects has been described [ -, , ] . The most common one is represented by arthralgia, which occurs in about % of patients. Most cases are mild to moderate, but about % of patients treated with Vemurafenib experienced a grade arthralgia [ , ] . These latter cases can be managed conservatively with non-steroidal anti-inflammatory drugs and acetaminophen however, severe cases may require a short course of steroid treatment [ ] Quite unusual but potentially life-threatening side effects are related to alterations of the cardiac rhythm, including the prolongation of cardiac repolarization and arrhythmia, which occurs in about % of patients. Hence, the monitoring of cardiac activity is mandatory in all Vemurafenib-treated patients however, the occurrence of absolute QTc values > ms [ , , ] that require prompt clinical management is quite rare.
. Cutaneous side effects from Vemurafenib
Cutaneous reactions are the most common side effects described during Vemurafenib treatment and impact significantly on patient's quality of life [ -, ] . As expected from the experience collected with other molecular targeted therapies, skin toxicity is related to the alteration of the wild-type BRAF signaling [ ].
The cutaneous adverse reactions affect a percentage of treated patients from to %, without difference of age and sex and can be classified according to the reaction pattern and time of appearance as follows
. . Rash
Literature data report the onset of a maculo-papular eruption in about % of treated patients [ , , , ] . Also in our experience, rash was the earliest and most frequent cutaneous side effect during Vemurafenib treatment % of treated patients of our series . From a clinical point of view, this rash could be similar to other drug-related exanthemas and it is characterized by the onset of maculae and follicular papules mainly distributed on the trunk and limbs Figure the head region is generally spared. Rush appears after a median time of days range -days , it is generally self-limiting and spontaneously resolve after a median of days from the onset range -. In the majority of cases, it is asymptomatic, even if some patients reported pruritus [personal unpublished data].
Cases that underwent skin biopsy show an inflammatory lympho-histiocytic lichenoid infiltrate, even if keratinocytes activation should be observed [ ]. The origin of this maculopapular eruption is still unclear however these features can explain the usefulness of topical steroids, as well as the anecdotic finding that rush did not occurred in patients receiving concomitant steroids for medical treatments related to other diseases.
Because of the self-limiting nature of this side effect, we recommend the routinely use of topical emollients steroids should be limited to symptomatic cases. Patients also have to be informed about the frequency and benignity of this rash however, persistent or clinically atypical exanthemas should be referred to an experienced dermatologist to avoid the risk of StevenJohnson Syndrome /Toxic Epidermal Necrolysis SJS/TEN [ , ] . Histologically, Vemurafenib-dependent warts were indistinguishable from common viral warts [ , ] standard wart treatments e.g. cryosurgery, keratolytic solutions, and diathermic coagulation usually are very effective.
. . Hyperkeratosis
In a percentage of Vemurafenib-treated patients, the induction of a keratinocytic hyperproliferation without signs of apoptosis results in an increased epidermal thickness [ ]. Plantar hyperkeratosis occurs mainly in areas under physical pressure, whereas diffuse hyperkeratotic follicular papules are observed mainly in the lower limbs and forearms Figure . In our experience, the median onset time of localized and diffuse hyperkeratosis is and days, respectively.
Topical keratolytic and emollient treatment can reduce hyperkeratosis, even if a complete resolution of this side effect was observed only after Vemurafenib discontinuation. 
. . Photosensitivity
Photosensitivity is another common phenomenon in Vemurafenib-treated patients. Even if this side effect does not represent a life-threatening condition, it can impact on patients' quality of life and could be difficult to manage [ , , , ] . Painful sunburns are an early phenomenon and may occur after few minutes of sun exposure UVA seems to play a more prominent role than UVB. In our experience, sunburns were observed in % of patients, also after a few days of treatment Figure Sun protection is mandatory in Vemurafenib-treated patients, and should be started together with BRAF inhibitor. Actinic conjunctivitis is also described as an early as well as a very late side effect. 
. . Effluvium and hair changes
In our experience, effluvium occur in % of patient, after a median time of days, usually without complete hair loss. Moreover, some patients experience a curling and ticking of the hair. Hair changes belong to the late onset side effects. All these phenomena could be explained by a paradoxical up-regulation of MAPK signaling [ -] .
. . Hands oedema and urticaria
A less frequent skin toxicity is represented by localized hand oedema, that developed in a few patients as an early side effect, usually within a month from the beginning of the treatment, in the absence of other signs of localized or diffuse oedema. In these patients, laboratory tests did not show renal toxicity or hypoalbuminemia. Morevover, cases of urticarial episodes during the Vemurafenib treatment are described, particularly in patients with a personal history of atopia normally, these episodes spontaneously resolve without drug suspension, and, hence, the relationship between Vemurafenib and urticaria remains to be ascertained [ -, ] .
. . Skin cancer
The first reports of skin toxicity obtained from phase I-III clinical trials and expanded access studies showed the onset of squamous cell carcinomas SCCs in up to % of Vemurafenibtreated patients [ ]. However, a pathology review of all lesions excised in phase II study revealed that % of reported SCCs were keratoacanthomas and the remaining %, welldifferentiated squamous cell carcinomas. More recent reports stated that incidence of SCCs and keratoacanthomas is about -%, respectively [ ].
Literature data hypothesize that keratoacanthomas and SCCs develop as a consequence of preexisting precancerous RAS mutations in keratinocytes of sun-exposed areas that are then activated by Vemurafenib through a paradoxical up-regulation of MAPK signaling [ , ] . This mechanism could explain the keratinocytes proliferation that leads to keratosis pilarislike lesions, palmo-plantar hyperkeratosis and hair changes in Vemurafenib-treated patients notably, the same side effects are also observed during treatment with sorafenib and MEK inhibitors. Along this line, chemoprevention of cutaneous SCCs by the subministration of systemic retinoids has been reported to be successful in Vemurafenib-treated [ ]. In our experience, also topical retinoid can significantly reduce the hyperkeratosis, with lower side effects unpublished data .
. Toxicity profiles of emerging BRAF inhibitors
The second-generation BRAFV inhibitor Dabrafenib has an acceptable safety profile. The percentage of patients that experience treatment-related side toxicities is lower respect to Vemurafenib and drug-related adverse events of grade occur in about % of patients.
Clinical trials with Dabrafenib and Vemurafenib show several differences in type, grade and frequencies of toxicities [ -, , ] . Cutaneous toxicities such as rash, hyperkeratosis and the development of non-melanoma skin cancers are less frequent in Dabrafenib-treated patients than inr those treated with Vemurafenib. In particular, skin carcinomas occur in % of patients treated with Vemurafenib as opposed to % during treatment with dabrafenib. Patients included in the phase I and II trials with Dabrafenib do not experienced photosensitivity, which could therefore be considered a Vemurafenib-specific toxicity.
Non-cutaneous toxicities such as arthralgia and fatigue also occur at an increased rate and grade for patients treated with Vemurafenib, whereas pyrexia is a specific toxicity seen with dabrafenib. The mechanisms underlying Dabrafenib-associated pyrexia are poorly understood and require further investigation. However, this condition can be successfully treated with steroids. No patient included in clinical trials with Dabrafenib experience liver toxicity [ , ] .
The increased incidence of high class toxicities scored with Vemurafenib than with Dabrafenib is likely to be explained by a number of factors, including differences in drug dosage the administered dose for Dabrafenib is lower than for Vemurafenib , RAF inhibitor potency, histopathologic assessment of cutaneous lesions, classification and reporting of toxicity. Moreover, the differences in phototype and exposure to exogenous risk factors for skin carcinomas of the different geographic populations enrolled in these studies could also play an important role.
. Conclusions
The efficacy of new drugs for the treatment of metastatic melanoma is accompanied by a new spectrum of toxicities, very different from those caused by conventional chemotherapy, but not less important. Therefore, it is crucial that clinicians develop the necessary skills for the early detection and management of these toxicities, in order to limit the need of interruption or suspension of these treatment and to offer the best chance of disease control. [ ] Anforth R, Fernandez-Peñas P, Long GV. Cutaneous toxicities of RAF inhibitors. Lancet Oncol. e -.
